close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.530 -0.120 (-2.13%)
Streaming Delayed Price Updated: 2:24 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.
Scaling up means having more power to bring to bear on core activities. 
Via The Motley Fool
Topics Artificial Intelligence
2024’s Hidden Gems: 7 Small-Caps Set for Explosive Growth
Small-cap stocks outperform larger companies on an indexed basis, but finding the best among them individually isn't always easy. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite stocks. 
Via The Motley Fool
This Stock Could Soar by 120%, According to Wall Street
Don't rush to buy shares just yet. 
Via The Motley Fool
Cathie Wood Just Made a Big Bet on Recursion Pharmaceuticals Stock. Will It Pay Off?
Cathie Wood just gave the company a huge vote of confidence. 
Via The Motley Fool
Unlocking AI investment opportunities in healthcare
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Recursion Pharmaceuticals: Q3 Earnings Insights
 
Via Benzinga
2 Risky Stocks With Massive Potential
Neither is doing well this year. 
Via The Motley Fool
Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock
 
Via Benzinga
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence
We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare. 
Via InvestorPlace
Topics Artificial Intelligence
Bayer and Recursion Focus Research Collaboration on Oncology
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Stocks to Buy for Their Proximity to Nvidia
Nvidia isn't the only AI stock on the market. These three companies stand to benefit from Nvidia's success while offering diversification. 
Via InvestorPlace
Topics Artificial Intelligence
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
The 7 Best Cathie Wood Stocks to Buy Now: November Edition
Dive into the dynamic world of Cathie Wood stocks, wagering on the disruptive tech gems shaping tomorrow's investment landscape. 
Via InvestorPlace
Is Recursion Pharmaceuticals Stock a Buy Now?
The company has grabbed plenty of headlines recently. 
Via The Motley Fool
2 Cathie Wood Stocks I'm Bullish On
These two next-gen biotechs could be outstanding buys for patient investors. 
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
This small-cap stock hopes to revolutionize drug discovery with the help of AI. 
Via The Motley Fool
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell
Pioneering businesses tend to carry big risks, but also the potential for big rewards. 
Via The Motley Fool
3 Extra-Speculative Stocks That Could Make You Very, Very Rich
Speculative stocks are a growth investor's dream—potential for untold riches, if you can find the stocks that will survive. 
Via InvestorPlace
1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid
One of these players could win in AI -- and in the healthcare market, in general. 
Via The Motley Fool
Topics Artificial Intelligence
2 AI Stocks That Aren't Worth the Hype
Even if you're bullish on AI, you may want to think twice about buying shares of these two companies. 
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ... 
Via Benzinga
Topics Artificial Intelligence
2 Cathie Wood Stocks That Could Deliver Exponential Returns
These two cutting-edge healthcare companies could be significantly undervalued right now. 
Via The Motley Fool
AI Investing: 12 Possible Ways To Maximize Your Returns
It all comes down to playing it smart and doing your research and to help you with that we present 12 micro/small cap AI&R stocks with descriptions of their businesses and their price-to-sales ratios,... 
Via Talk Markets
Topics Artificial Intelligence
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today. 
Via InvestorPlace
3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too
Cathie Wood is loading up on these healthcare stocks. 
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
They're both liable to grow by a lot, but one of them is a safer bet in the near term. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today